-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
RmNjod+iBNpQU1SrG3QcBJTsZKN4crlN5rtRejt1pWxh9O+CONe5Jn3vVvczHNYV
mOcCYv6bE0tR/i2Ht7kMJw==
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q THE SECURITIES EXCHANGE ACT OF 1934. THE SECURITIES EXCHANGE ACT.
(Mark One)
[ X ]
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
For the quarterly period ended September 30, 2000.
[ ]
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF
For the transition period from __________ to __________
Commission file number 0-27610
LCA-Vision Inc.
(Exact name of registrant as specified in its charter)
Delaware | 11-2882328 | |||||||
(State or other jurisdiction of
incorporation or organization) |
(IRS Employer
Identification No.) | |||||||
7840 Montgomery Road, Cincinnati, Ohio 45236
(Address of principal executive offices)
(513) 792-9292
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes |
X |
No |
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 49,888,197 shares as of October 31, 2000.
LCA-Vision Inc.
INDEX
Facing Sheet | 1 | |||||||||||
Index | 2 | |||||||||||
Part I. | Financial Information | |||||||||||
Item 1. | Financial Statements | |||||||||||
Unaudited Condensed Consolidated Balance Sheets at September 30, 2000 and December 31, 1999 | ||||||||||||
3 | ||||||||||||
Unaudited Condensed Consolidated Statements of Income for the Three
and Nine Months Ended September 30, 2000 and 1999 |
||||||||||||
4 | ||||||||||||
Unaudited Condensed Consolidated Statements of Cash Flows for the
Nine Months Ended September 30, 2000 and 1999 |
||||||||||||
5 | ||||||||||||
Notes to Unaudited Condensed Consolidated Financial Statements | 6 | |||||||||||
Item 2. | Management's Discussion and Analysis of Financial Condition and
Results of Operations |
|||||||||||
9 | ||||||||||||
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 12 | ||||||||||
Part II. | Other Information | |||||||||||
Item 1. | Legal Proceedings | 13 | ||||||||||
Item 2. | Changes in Securities and Use of Proceeds | |||||||||||
Item 3. | Defaults Upon Senior Securities | |||||||||||
Item 4. | Submission of Matters to a Vote of Security Holders | |||||||||||
Item 5. | Other Information | |||||||||||
Item 6. | Exhibits and Reports on Form 8-K | 15 | ||||||||||
Signatures | 16 |
LCA-Vision Inc. | |||||
Condensed Consolidated Balance Sheets | |||||
September 30, 2000 and December 31, 1999 | |||||
Dollars in Thousands | |||||
(Unaudited) | |||||
September 30, 2000 | December 31, 1999 | ||||
Assets | |||||
Current Assets | |||||
Cash and cash equivalents | $24,876 | $11,891 | |||
Short-term investments | 14,528 | 37,299 | |||
Accounts receivable, net | 1,121 | 1,971 | |||
Deferred tax asset | 631 | 631 | |||
Pre-paid expenses, inventory and other | 1,954
-------------- |
1,984
-------------- | |||
Total current assets | 43,110 | 53,776 | |||
Property and equipment, net | 15,788 | 9,726 | |||
Goodwill, net | 790 | 902 | |||
Deferred tax asset | 13,162 | 12,950 | |||
Obligations due from shareholders | 708 | 708 | |||
Investment in unconsolidated business | 271 | 254 | |||
Other assets | 2,242
-------------- |
6,974
-------------- | |||
Total assets | $76,071
======== |
$85,290
======== | |||
Liabilities and Shareholders' Investment | |||||
Current liabilities | |||||
Accounts payable | $3,945 | $2,458 | |||
Accrued liabilities and taxes | 1,431 | 1,821 | |||
Debt maturing in one year | 301
-------------- |
676
-------------- | |||
Total current liabilities | 5,677 | 4,955 | |||
Long-term debt | 94 | 250 | |||
Minority equity interest | 34 | 40 | |||
Commitments and contingencies | - | - | |||
Shareholders' investment | |||||
Preferred stock | - | - | |||
Common stock ($0.001 par value; 52,086,866 shares | |||||
and 51,513,989 shares issued) | 111 | 111 | |||
Contributed capital | 89,572 | 88,348 | |||
Warrants | 2,105 | 6,362 | |||
Notes receivable from shareholders | (906) | - | |||
Common stock in treasury, at cost (1,790,373 shares | (5,034) | (30) | |||
and 10,909 shares) | |||||
Accumulated deficit | (15,585) | (14,771) | |||
Foreign currency translation adjustment | 3
-------------- |
25
-------------- | |||
Total shareholders' investment | 70,266
-------------- |
80,045
-------------- | |||
Total liabilities and shareholders' investment | $76,071
========= |
$85,290
======== |
The Notes to the unaudited Condensed Consolidated Financial Statements are an integral part of this statement.
LCA-Vision Inc. | ||||||
Condensed Consolidated Statements of Income | ||||||
for the Three and Nine Months Ended September 30, 2000 and 1999 | ||||||
(Unaudited) | ||||||
Dollars in thousands except per-share data | ||||||
Three months ended September 30 | Nine months ended September 30 | |||||
Revenues | 2000
------------- |
1999
------------- |
2000
------------- |
1999
------------- | ||
Laser refractive surgery | $15,590 | $14,882 | $48,745 | $42,617 | ||
Other | 68
------------- |
91
------------- |
194
------------- |
953
------------- | ||
Total Revenues | 15,658 | 14,973 | 48,939 | 43,570 | ||
Operating costs and expenses | ||||||
Medical professional and license fees | 3,379 | 6,434 | 12,456 | 18,635 | ||
Direct costs of service | 5,565 | 3,108 | 15,725 | 8,396 | ||
General and administrative expenses | 3,841 | 2,519 | 10,883 | 7,304 | ||
Marketing and advertising | 2,808 | 1,162 | 11,076 | 2,600 | ||
Depreciation | 1,036 | 775 | 2,657 | 2,211 | ||
Restructuring accrual | -
------------- |
-
------------- |
-
------------- |
(150)
------------- | ||
Operating income (loss) | (971) | 975 | (3,858) | 4,574 | ||
Equity in earnings (loss)from unconsolidated | 15 | (153) | 24 | 264 | ||
Businesses | ||||||
Minority Equity Interest | (22) | - | (16) | - | ||
Interest (expense) | (10) | (25) | (50) | (145) | ||
Interest income | 648 | 632 | 2,044 | 908 | ||
Other income (expense) | 37
------------- |
4
------------- |
585
------------- |
(55)
------------- | ||
Income (loss) before taxes on income | (303) | 1,433 | (1,271) | 5,546 | ||
Income tax expense/(benefit) | (102)
------------- |
10
------------- |
(464)
------------- |
18
------------- | ||
Net income (loss) | (201) | 1,423 | (807) | 5,528 | ||
Preferred stock dividends | - | 12 | - | 140 | ||
Income (loss) applicable to common stock | $(201)
======== |
$1,411
======== |
$(807)
======== |
$5,388
======== | ||
Income per common share | ||||||
Basic | $0.00 | $0.03 | $(0.02) | $0.12 | ||
Diluted | $0.00 | $0.03 | $(0.02) | $0.11 | ||
Weighted average shares outstanding | ||||||
Basic | 50,921 | 51,227 | 51,559 | 46,819 | ||
Diluted | 50,921 | 54,389 | 51,559 | 50,104 |
The Notes to the unaudited Condensed Consolidated Financial Statements are an integral part of this statement.
LCA-Vision Inc. | ||||||
Condensed Consolidated Statements of Cash Flows | ||||||
For the Nine Months Ended September 30, 2000 and 1999 | ||||||
(Unaudited) | ||||||
Nine Months Ended | ||||||
September 30, | ||||||
2000
------------ |
1999
------------ | |||||
Cash flows from operating activities: | ||||||
Net income/(loss) | $(807) | $5,388 | ||||
Adjustments to reconcile net income to net cash provided by | ||||||
operating activities: | ||||||
Depreciation and amortization | 2,657 | 2,211 | ||||
Amortization of warrant | 720 | - | ||||
Equity in earnings of unconsolidated affiliates | (7) | (264) | ||||
Compensation paid in common stock | - | 375 | ||||
Changes in working capital: | ||||||
Restructuring provision | - | (150) | ||||
Accounts receivable | 850 | (804) | ||||
Prepaid expenses, inventory and other | 30 | (301) | ||||
Accounts payable | 1,581 | (457) | ||||
Accrued liabilities and other | (398)
------------ |
812
------------ | ||||
Net cash provided by operations | 4,626 | 6,810 | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment | (8,607) | (846) | ||||
Beginning cash of consolidated affiliate | - | 1,032 | ||||
Proceeds from sale of equipment | - | 200 | ||||
Purchase of short-term investments | (52,756) | (35,199) | ||||
Maturity of short-term investments | 75,527 | - | ||||
Other, net | (280)
------------ |
7
------------ | ||||
Net cash provided (used) by investing activities | 13,884 | (34,806) | ||||
Cash flows from financing activities: | ||||||
Principal payments of long-term notes, debt and capital lease |
(535) |
(2,470) | ||||
obligations | ||||||
Shares repurchased for Treasury Stock | (5,004) | - | ||||
Exercise of stock options & warrants | 918 | 944 | ||||
Distribution to minority equity investees | (6) | - | ||||
Increase in notes receivable from shareholders | (906) | - | ||||
Proceeds from sale of common stock | - | 36,715 | ||||
Cash dividends paid | - | (462) | ||||
Increase in notes payable | 8
------------ |
-
------------ | ||||
Net cash provided (used) by financing activities | (5,525) | 34,727 | ||||
Increase in cash and cash equivalents | 12,985 | 6,731 | ||||
Cash and cash equivalents at beginning of period | 11,891
------------ |
6,496
------------ | ||||
Cash and cash equivalents at end of period | $24,876
======= |
13,227
======= | ||||
The Notes to the unaudited Condensed Consolidated Financial Statements are an integral part of this statement. |
LCA-Vision Inc.
Notes to Condensed Consolidated Financial Statements
for the Three and Nine Months Ended September 30, 2000 and 1999
(Unaudited)
1. Summary of Significant Accounting Policies
The September 30, 2000 and 1999 financial data are unaudited; however, in the opinion of the Company, such data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the interim periods. The December 31, 1999 Condensed Consolidated Balance Sheet has been derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. We suggest that these financial statements be read together with the financial statements and notes included in our annual report on Form 10-K.
Business
We are a leading developer and operator of free-standing laser refractive surgery centers. Our laser refractive surgery centers provide the staff, facilities, equipment and support services for performing various corrective eye surgeries that employ state-of-the-art laser technologies. The laser vision correction surgeries performed in our centers are primarily laser in situ keratomileusis ("LASIK") and photorefractive keratectomy ("PRK"). We previously managed multi-specialty laser surgery programs at medical facilities on a contract basis.
Revenue by source is comprised of:
- Laser refractive surgery - fees for surgeries performed at our consolidated centers.
- Other - management fees for operating laser vision correction centers of investees; contractual fees for managing multi-specialty laser surgery programs at hospitals; marketing and education program fees; license fees; and miscellaneous sources.
Certain operating costs and expenses:
- Medical professional and license fees - per procedure fees for the ophthalmologist performinglaser vision correction and the per procedure license fee in the U.S. paid to laser manufacturers.
- Direct costs of services - center rent and utilities, equipment lease and maintenance costs, surgical supplies, center physician and staff expense, and costs related to other revenue.
- General and administrative - headquarters staff expense and other overhead costs.
- Depreciation and amortization - periodic charges to income for the costs of equipment and intangible assets recorded in the condensed consolidated balance sheet.
Consolidation Policy
We use two different methods to report our investments in our subsidiaries and other companies - consolidation and the equity method.
Consolidation
We use consolidation when we own a majority of the voting stock of the subsidiary. This means the accounts of our subsidiaries are combined with our accounts. We eliminate intercompany balances and transactions when we consolidate these accounts. Our condensed consolidated financial statements include the accounts of:
- LCA-Vision Inc.,
- LCA-Vision (Ohio), Inc.,
- Refractive Centers International, Inc. and Subsidiaries
- LCA-Vision (Canada) Inc. and Subsidiaries, and
- The Baltimore Laser Sight Center, Ltd. (since July 1999).
Equity Method
We use the equity method to report investments in businesses where we hold a 20% to 50% voting interest, giving us the ability to exercise significant influence, but not control, over operating and financial policies. Under the equity method we report:
- our interest in the entity as an investment in our Condensed Consolidated Balance Sheets, and
- our percentage share of the earnings (losses) in our Condensed Consolidated Statements of Operations.
We own 43% of Silmalaseri Oy and 50% of Cole LCA Vision LLC and report our investments under the equity method. In the first half of 1999, Baltimore Laser Sight Center (Baltimore) was accounted for using the equity method, and the company recorded management fees in other revenue. In July 1999, our ownership percentage in Baltimore increased to 97 percent, and since that time we have consolidated the financial statements into LCA-Vision Inc.
Use of Estimates
Management makes estimates and assumptions when preparing financial statements under generally accepted accounting principles. These estimates and assumptions affect various matters including:
- our reported amounts of assets and liabilities in our Condensed Consolidated Balance Sheets at the dates of the financial statements,
- our disclosure of contingent liabilities at the dates of the financial statements, and
- our reported amounts of revenues and expenses in our Condensed Consolidated Statements of Income during the reporting periods.
Actual amounts could differ from those estimates.
Per Share Data
Basic per share data is income applicable to common shareholders divided by the weighted average common shares outstanding. Diluted per share data is income applicable to common shareholders divided by the weighted average common shares outstanding plus the potential issuance of common shares if stock options or warrants were exercised or convertible preferred stock were converted into common stock.
Following is a reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2000 and 1999 (in thousands, except per share amounts):
Three Months Ended | Nine Months Ended | ||||
September 30, | September 30, | ||||
2000 | 1999 | 2000 | 1999 | ||
Basic Earnings per Share | |||||
Income/(loss) available to common shareholders | $(201) | $1,411 | $(807) | $5,388 | |
Weighted average shares outstanding | 50,921 | 51,227 | 51,559 | 46,819 | |
Basic earnings (loss) per share | $0.00 | $0.03 | $(0.02) | $0.12 | |
Diluted earnings per share | |||||
Income/(loss) available to common shareholders | $(201) | $1,411 | $(807) | $5,388 | |
Dividends to preferred shareholders | - | 12 | - | 140 | |
Net income/(loss) | (201) | 1,423 | (807) | 5,528 | |
Weighted average shares outstanding | 50,921 | 51,227 | 51,559 | 46,819 | |
Effect of dilutive securities | |||||
Convertible preferred stock | - | 284 | - | 1,082 | |
Stock options | - | 2,794 | - | 2,143 | |
Warrants | - | 84 | - | 60 | |
Weighted average common shares and potential dilutive shares | 50,921 | 54,389 | 51,559 | 50,104 | |
Diluted earnings (loss) per share | $0.00 | $0.03 | $(0.02) | $0.11 |
2. Shareholders' Investment
Common Stock
During the three months ended September 30, 2000, 8,988 shares of common stock were issued to individuals who exercised stock options. The average exercise price was $1.14 per share.
Warrants
Warrants to purchase 800,000 shares were issued during the third quarter of 1999 of which 200,000 were exercisable at that time and the remainder became exercisable in equal installments of 200,000 each as of December 31, 1999, 2000 and 2001. In the third quarter of 2000, the Company expensed $310,000 for the repurchase of 400,000 unvested warrants from Cole National Corporation.
Generally accepted accounting principles requires us to assign a value to the warrants for the services to be rendered. We used the Black-Scholes method to determine the amount, or expected amount, of compensation for each block of warrants as it becomes exercisable. The amount calculated is recorded as part of other assets and amortized over the three-year term of the agreement with Cole National Corporation to market laser vision correction as a managed care benefit. Amortization expense of $177,000 was recorded for the third quarter of 2000, bringing the year-to-date amortization expense to $649,000.
3. Segment Information
We operate in one segment - laser refractive surgery. Following is a table summarizing the results of our Canadian operations included in the Condensed Consolidated Statement of Income for the three and nine months ended September 30, 2000 and 1999 (in thousands):
Three Months Ended | Nine Months Ended |
September 30, |
September 30, | ||||
2000
---------- |
1999
---------- |
2000
---------- |
1999
---------- | ||
Revenues | $378 | $407 | $1,501 | $1,226 | |
Operating profit (loss) | (39) | (66) | (96) | 13 |
4. Commitments and Contingencies
We are a defendant and counter-claimant in a consolidated case entitled Cabrini Development Council, et al. v. LCA-Vision Inc., et al., which was commenced in October, 1997 in the Supreme Court of the State of New York, County of New York and subsequently removed to the United States District Court for the Southern District of New York. Also named as co-defendants are various current and former employees, officers and directors. The case involves claims and counterclaims asserted by and against us, and two other members of a New York limited liability company formerly engaged in operating a laser refractive surgery center, and arises out of the cessation of operations of such limited liability company.
Judge Chin recently ruled that the court lacks subject matter jurisdiction over the controversy. The decision may be appealed by either party, or the claims could be pursued in the New York State Supreme Court.
In the opinion of management this action will not have a material adverse effect on our financial position or results of operations.
Item 2. Management's Discussion and Analysis of Financial Condition Results of Operations.
his quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors. For a discussion of important factors that could affect our results, refer to the Overview and financial statement line item discussions set forth in Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A").
"MD&A" is an analysis of our operating results for the three and nine months ended September 30, 2000 and 1999 and our financial condition as of September 30, 2000. It explains why our revenues and costs changed, our overall financial condition, and other matters.
Results of Operations - Revenues
Laser refractive surgery
Laser refractive surgery revenue generally includes three components: facility fee, royalty fee, and medical professional fees. Certain states prohibit us from practicing medicine, employing physicians to practice medicine on our behalf or employing optometrists to render optometry services on our behalf. Revenues and direct costs from centers in such states do not include the medical professionals fee component. The contribution from laser refractive surgery procedures for each of the three and nine months ended September 30, 2000 and 1999 were (dollars in thousands):
Three Months Ended | Nine Months Ended | ||||||
September 30, | September 30, | ||||||
2000
---------- |
1999
---------- |
2000
---------- |
1999
---------- | ||||
Revenue | 15,590 | 14,882 | 48,745 | 42,617 | |||
Less: | |||||||
Medical professional and | |||||||
License fees | 3,379
---------- |
6,434
---------- |
12,456
---------- |
18,635
---------- | |||
Contribution | 12,211 | 8,448 | 36,289 | 23,982 |
The following table illustrates the growth of laser vision correction procedures performed at our centers.
Consolidated |
2000
---------- |
1999
---------- | |
Q1 | 12,504 | 7,591 |
Q2 | 13,888 | 8,365 |
Q3 | 16,341 | 8,769 |
Q4 | 8,541
---------- | |
Year | 33,266 |
Other revenues
Other revenues declined because we chose to exit the surgery management business for hospitals. Also contributing to the decrease in other revenue is the 1999 change in the consolidation method for the Baltimore Laser Sight Center ("Baltimore").
Medical professional and license fees
License fees decreased by $351,000 in the third quarter of 2000 from the third quarter of 1999. The reduction of the VISX per procedure price decrease from $260 to $110 more than offset the increase in license fees associated with the increase in procedure volume from 8,769 in the third quarter of 1999 to 16,341 in the third quarter of 2000. Medical fees decreased by approximately $2,700,000 in the third quarter of 2000 from the third quarter of 1999, despite an 86 percent increase in procedure volume. Physician contracts were renegotiated during the second quarter of 2000 to enable the company to be competitive at the lower pricing levels.
Direct costs of services
The table below provides information related to our direct costs of services (dollars in thousands).
Three Months Ended | Nine Months Ended | |||||
September 30, | September 30, | |||||
2000
---------- |
1999
---------- |
2000
---------- |
1999
---------- | |||
Laser refractive surgery | ||||||
Employee costs | $2,870 | $1,156 | $8,259 | $3,110 | ||
Equipment rent and maintenance | 1,365 | 1,042 | 3,821 | 2,799 | ||
Facility rent and utilities | 659 | 318 | 1,586 | 922 | ||
Supplies, gases and other | 666
---------- |
549
---------- |
2,043
---------- |
1,434
---------- | ||
5,560 | 3,065 | 15,709 | 8,265 | |||
Hospital and other | 5
---------- |
43
---------- |
16
---------- |
131
---------- | ||
$5,565 | $3,108 | $15,725 | $8,396 |
Direct costs of services include the salary component of physician compensation, staffing, equipment, medical supplies, and facility costs to operate laser vision correction centers. These direct costs increased in the third quarter of 2000 by $2,457,000 over the third quarter of 1999, largely because of the increase in the number of centers in operation. The average direct cost per center per month increased from $44,420 in the third quarter of 1999 to $61,099 in the third quarter of 2000. The change in the business model from open access to LasikPlus results in a salary commitment to physicians in the year 2000 that was not present in 1999. These physician salaries are recorded in employee costs.
Medical supplies increased by $117,000 in the third quarter of 2000 as a result of higher procedure volumes. Rental expense for equipment and facilities increased by $323,000 in the third quarter of 2000 to support new and expanded laser vision correction centers.
General and administrative
General and administrative expenses increased by $1,322,000 in the third quarter of 2000 from the third quarter of 1999. Staffing costs increased by $404,000 as we expanded our national call center and strengthened our corporate management team. Sequentially, general and administrative expenses grew by under four percent in the third quarter of 2000. The repurchase of unvested warrants from Cole National Corporation and the amortization of vested warrants increased general and administrative expenses by $497,000 in the third quarter of 2000 over the third quarter of 1999.
Marketing and advertising expenses
Marketing and advertising expenses increased by $1,646,000 in the third quarter of 2000 from the third quarter in 1999. With the change from open access to LasikPlus, the company, not the doctor, takes responsibility for patient acquisition. Compared to the second quarter of 2000, marketing and advertising expenditures decreased by $1,333,000.
Depreciation and amortization
Depreciation and amortization expense increased by $261,000 in the third quarter of 2000 from the third quarter of 1999 because of the depreciation of capitalized costs of new center openings.
Non-operating income and expenses
Interest expense decreased due to the significant reduction in debt. Interest income increased due to interest earned on overnight investments and short-term government securities.
Liquidity and Capital Resources
Our primary sources of liquidity for the next year are expected to be:
- cash generated from operations
- proceeds from the exercise of stock options
- credit facility and lease financing, as necessary
Net cash provided by operating activities in the first nine months of 2000 was $4,626,000. Proceeds from stock options exercised in the first nine months were $918,000. The sum of these two sources of cash combined with the use of approximately $3,064,000 in cash reserves were sufficient to finance our capital expenditures and debt repayment in the first nine months of the year.
On June 6, 2000 the Board of Directors authorized the repurchase of up to five million shares of the company's common stock. Through September 30, 2000, the company has repurchased approximately 1.8 million shares for an aggregate value of $5,004,000.
As of September 30, 2000 we have cash and cash equivalents of $24,876,000. In addition, we have short-term investments of $14,528,000.
During the second quarter of 2000, the directors initiated a program to encourage additional direct stock ownership by senior management of the company. The Company offered loans to nine key managers and directors for the purpose of purchasing shares in the open market. Each loan is a personal obligation of the borrower, and is evidenced by a promissory note. The interest rate on the notes is prime less one and one-half percent. The notes have a maximum term of three years, and contain provisions for early repayment. A total of $906,000 has been loaned under this program.
As of September 30, 2000 we maintained a $10,000,000 revolving credit facility with The Provident Bank ("Provident"). $800,000 of the facility is being used to secure letters of credit. In addition to the $9,200,000 of unused credit under this facility, the company has a $10,000,000 credit commitment for funding acquisitions. Both of these credit arrangements expire June 30, 2001.
Factors That May Affect Future Results and Market Price of Stock
For a detailed discussion that may affect future results, please refer to the Company's last 10-K and 10-Q. No material new risks have developed since the filing of these reports.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
The carrying values of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short maturity of these instruments.
We have historically had very low exposure to changes in foreign currency exchange rates, and as such, have not used derivative financial instruments to manage foreign currency fluctuation risk.
Part II. | Other Information |
Item 1. | Legal Proceedings |
Commitments and Contingencies | |
We are a defendant and counter-claimant in a consolidated case entitled Cabrini Development Council, et al. v. LCA-Vision Inc., et al., which was commenced in October, 1997 in the Supreme Court of the State of New York, County of New York and subsequently removed to the United States District Court for the Southern District of New York. Also named as co-defendants are various current and former employees, officers and directors. The case involves claims and counterclaims asserted by and against us, and two other members of a New York limited liability company formerly engaged in operating a laser refractive surgery center, and arises out of the cessation of operations of such limited liability company. | |
Judge Chin recently ruled that the court lacks subject matter jurisdiction over the controversy. The decision may be appealed by either party, or claims could be pursued in the New York Supreme Court. | |
In the opinion of management this action will not have a material adverse effect on our financial position or results of operations. | |
Item 2. | Changes in Securities and Use of Proceeds.
None |
Item 3. | Defaults upon Senior Securities.
None |
Item 4. | Submission of Matters to a Vote of Security Holders
None |
Item 5. | Other Information.
None |
Part II. | Other Information (continued) | ||||
Item 6. | Exhibits and Reports on Form 8-K. | ||||
(a) | Exhibits | ||||
Exhibit | |||||
Number | Description of Exhibit | ||||
27 | Financial Data Schedule | ||||
(b) | Reports on Form 8-K | ||||
1) | Form 8-K dated July 27, 2000 containing a press release reporting the opening of 27th U.S. LasikPlus facility on August 7, 2000 in Rockville, Maryland. | ||||
2) | Form 8-K dated August 3, 2000 containing a press release reporting second quarter financial results. | ||||
3) | Form 8-K dated September 6, 2000 containing a press release announcing its plan to open a fourth value-priced LasikPlus Center in both the Atlanta and Washington areas within the next three weeks. | ||||
4) | Form 8-K dated September 19, 2000 containing a press release reporting the opening of three value-priced LasikPlus centers in the Greater Philadelphia/Wilmington suburban area. | ||||
5) | Form 8-K dated October 3, 2000 containing a press release reporting an 86% increase in consolidated procedure volume for the third quarter of 2000. |
Signatures
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
LCA-VISION INC.
Date | ________________ | /s/ Stephen N. Joffe
Stephen N. Joffe President and Chief Executive Officer | |||||
Date | ________________ | /s/ Alan Buckey
Alan Buckey Chief Financial Officer | |||||